136 related articles for article (PubMed ID: 27123883)
21. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
22. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas.
Baumgarten P; Brokinkel B; Zinke J; Zachskorn C; Ebel H; Albert FK; Stummer W; Plate KH; Harter PN; Hasselblatt M; Mittelbronn M
Histol Histopathol; 2013 Sep; 28(9):1157-66. PubMed ID: 23475388
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy: What is its role in meningioma?
Sherman WJ; Raizer JJ
Expert Rev Neurother; 2012 Oct; 12(10):1189-95; quiz 1196. PubMed ID: 23082735
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin has promising antineoplastic activity in high-grade meningioma.
Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
[TBL] [Abstract][Full Text] [Related]
26. Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in vivo and in vitro.
Ragel BT; Gillespie DL; Kushnir V; Polevaya N; Kelly D; Jensen RL
Neurosurgery; 2006 Nov; 59(5):1109-20; discussion 1120-1. PubMed ID: 17143245
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.
Shih KC; Chowdhary S; Rosenblatt P; Weir AB; Shepard GC; Williams JT; Shastry M; Burris HA; Hainsworth JD
J Neurooncol; 2016 Sep; 129(2):281-8. PubMed ID: 27311730
[TBL] [Abstract][Full Text] [Related]
28. Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells.
Andrae N; Kirches E; Hartig R; Haase D; Keilhoff G; Kalinski T; Mawrin C
Eur J Cancer; 2012 Aug; 48(12):1831-41. PubMed ID: 22391574
[TBL] [Abstract][Full Text] [Related]
29. Treatment of unresectable skull base meningiomas with somatostatin analogs.
Schulz C; Mathieu R; Kunz U; Mauer UM
Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
[TBL] [Abstract][Full Text] [Related]
30. [Meningioma: management of the most common brain tumour].
Hundsberger T; Surbeck W; Hader C; Putora PM; Conen K; Roelcke U
Praxis (Bern 1994); 2016 Apr; 105(8):445-51. PubMed ID: 27078728
[TBL] [Abstract][Full Text] [Related]
31. Treatment of high risk or recurrent meningiomas with hydroxyurea.
Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2002 Mar; 9(2):156-8. PubMed ID: 11922703
[TBL] [Abstract][Full Text] [Related]
32. Regulation of vascular endothelial growth factor secretion in human meningioma cells.
Tsai JC; Hsiao YY; Teng LJ; Shun CT; Chen CT; Goldman CK; Kao MC
J Formos Med Assoc; 1999 Feb; 98(2):111-7. PubMed ID: 10083766
[TBL] [Abstract][Full Text] [Related]
33. [The significance of biological intracranial meningioma behaviour for their long-term management].
Netuka D; Kramář F; Belšan T; Hrabal P; Cernotová I; Ostrý S; Bradáč O; Preiss M; Beneš V
Rozhl Chir; 2012 Jun; 91(6):322-6. PubMed ID: 23078225
[TBL] [Abstract][Full Text] [Related]
34. Successful mifepristone treatment of recurrent, inoperable meningioma.
Haak HR; de Keizer RJ; Hagenouw-Taal JC; van Seters AP; Vielvoye GJ; van Dulken H
Lancet; 1990 Jul; 336(8707):124-5. PubMed ID: 1975312
[No Abstract] [Full Text] [Related]
35. Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Int J Neurosci; 2016 Nov; 126(11):1002-6. PubMed ID: 26365467
[TBL] [Abstract][Full Text] [Related]
36. A five year-old child with clear cell petro-clival meningioma: case report with clinical and histopathological long-term follow-up.
Juratli TA; Geiger KD; Weigel P; von der Hagen M; Daubner D; Pinzer T; Hahn G; Schackert G; Kirsch M
Childs Nerv Syst; 2015 Nov; 31(11):2193-8. PubMed ID: 26077595
[TBL] [Abstract][Full Text] [Related]
37. Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
Yoshikawa A; Nakada M; Ohtsuki S; Hayashi Y; Obuchi W; Sato Y; Ikeda C; Watanabe T; Kawahara Y; Hasegawa T; Sabit H; Kita D; Hayashi Y; Nakanuma Y; Terasaki T; Hamada JI
Neuropathol Appl Neurobiol; 2012 Feb; 38(1):105-10. PubMed ID: 21696419
[No Abstract] [Full Text] [Related]
38. Effect of systemic celecoxib on human meningioma after intracranial transplantation into nude mice.
Friedrich S; Schwabe K; Grote M; Krauss JK; Nakamura M
Acta Neurochir (Wien); 2013 Jan; 155(1):173-82. PubMed ID: 23143216
[TBL] [Abstract][Full Text] [Related]
39. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.
Grunberg SM; Weiss MH; Russell CA; Spitz IM; Ahmadi J; Sadun A; Sitruk-Ware R
Cancer Invest; 2006 Dec; 24(8):727-33. PubMed ID: 17162554
[TBL] [Abstract][Full Text] [Related]
40. High-grade meningiomas: new avenues for drug treatment?
Preusser M; Berghoff AS; Hottinger AF
Curr Opin Neurol; 2013 Dec; 26(6):708-15. PubMed ID: 24184974
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
